Gold nanoparticle nanovaccines with LLO or GAPDH peptides prevent neonatal listeriosis better than ampicillin in pregnant mice.
Background
Neonatal listeriosis, caused by Listeria monocytogenes, remains a significant concern, often leading to severe complications and mortality. While ampicillin is the primary antimicrobial therapy for established infections in adults and neonates, effective prophylactic treatments are currently lacking. This gap highlights the urgent need for preventative strategies, especially for vulnerable populations like pregnant women and their offspring. Exploring novel approaches like nanovaccines, which can leverage specific antigenic peptides to elicit robust immune responses, offers a promising avenue to address this unmet medical need.
Study Design
Researchers compared nanovaccines against prenatal or postnatal ampicillin treatments in pregnant female mice to prevent neonatal listeriosis. Nanovaccines were prepared using gold nanoparticles conjugated with either listeriolysin O (LLO) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) peptides. These nanovaccines were inoculated into pregnant females, and their efficacy was evaluated against the development of neonatal listeriosis and associated comorbidities. The study also assessed the immunomodulatory capacity of these nanovaccines on blood cells from listeriosis patients, using assays to determine specific immunogenic responses.
Results
Nanovaccines prepared with gold nanoparticles and either LLO or GAPDH peptides significantly prevented neonatal listeriosis and the appearance of comorbidities in pregnant female mice. This prophylactic effect was superior to both pre- and postnatal ampicillin treatment. The study demonstrated that these nanovaccines offered a more robust protective outcome, suggesting a potent immune-mediated mechanism. Furthermore, evaluating the immunomodulatory ability of nanovaccines on blood cells from listeriosis patients revealed:
The use of GAPDH nanovaccines exhibited a strong and specific immunogenic capacity, indicating their potential as putative immunotherapies in listeriosis.
Key Findings
- Nanovaccines with LLO or GAPDH peptides prevented neonatal listeriosis in pregnant mice.
- Nanovaccine prophylaxis was superior to both pre- and postnatal ampicillin treatment.
- GAPDH nanovaccines demonstrated strong and specific immunogenic capacity in patient blood cells.
- The nanovaccines effectively prevented the appearance of listeriosis-related comorbidities.
Why It Matters
This research introduces a compelling prophylactic strategy for listeriosis, particularly for preventing neonatal infections, which could significantly reduce morbidity and mortality. Gold nanoparticle-based nanovaccines with specific antigenic peptides like LLO or GAPDH offer a superior alternative to current antibiotic-centric approaches, which lack prophylactic efficacy. The finding that GAPDH nanovaccines possess strong immunogenic capacity also opens doors for their development as immunotherapies for active listeriosis, potentially shifting treatment paradigms from purely antimicrobial to immune-boosting. This could lead to new protocols for pregnant individuals at risk, moving beyond reactive antibiotic use to proactive immune protection.
listeriosis
nanovaccine
gold-nanoparticles
llo-peptide
gapdh-peptide
immunomodulation